Your browser doesn't support javascript.
Metabolomic analyses reveal new stage-specific features of COVID-19.
Jia, Hongling; Liu, Chaowu; Li, Dantong; Huang, Qingsheng; Liu, Dong; Zhang, Ying; Ye, Chang; Zhou, Di; Wang, Yang; Tan, Yanlian; Li, Kuibiao; Lin, Fangqin; Zhang, Haiqing; Lin, Jingchao; Xu, Yang; Liu, Jingwen; Zeng, Qing; Hong, Jian; Chen, Guobing; Zhang, Hao; Zheng, Lingling; Deng, Xilong; Ke, Changwen; Gao, Yunfei; Fan, Jun; Di, Biao; Liang, Huiying.
  • Jia H; Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
  • Liu C; Dept of Medical Biochemistry and Molecular Biology, School of Medicine, Jinan University, Guangzhou, China.
  • Li D; These authors contributed equally to this study.
  • Huang Q; Guangdong Institute of Microbiology, Guangdong Academy of Sciences, State Key Laboratory of Applied Microbiology Southern China, Guangzhou, China.
  • Liu D; These authors contributed equally to this study.
  • Zhang Y; Clinical Data Center, Guangdong Provincial People's Hospital/Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Ye C; These authors contributed equally to this study.
  • Zhou D; Clinical Data Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
  • Wang Y; These authors contributed equally to this study.
  • Tan Y; Big Data and Machine Learning Laboratory, Chongqing University of Technology, Chongqing, China.
  • Li K; These authors contributed equally to this study.
  • Lin F; Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
  • Zhang H; These authors contributed equally to this study.
  • Lin J; Clinical Data Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
  • Xu Y; Metabo-Profile Biotechnology (Shanghai) Co. Ltd, Shanghai, China.
  • Liu J; Metabo-Profile Biotechnology (Shanghai) Co. Ltd, Shanghai, China.
  • Zeng Q; Dept of Medical Biochemistry and Molecular Biology, School of Medicine, Jinan University, Guangzhou, China.
  • Hong J; Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
  • Chen G; Clinical Data Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
  • Zhang H; Dept of Occupational and Environmental Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zheng L; Metabo-Profile Biotechnology (Shanghai) Co. Ltd, Shanghai, China.
  • Deng X; Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
  • Ke C; Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
  • Gao Y; Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
  • Fan J; Dept of Pathophysiology, School of Medicine, Jinan University, Guangzhou, China.
  • Di B; Institute of Geriatric Immunology, Dept of Microbiology and Immunology, School of Medicine, Dept of Neurology, Affiliated Huaqiao Hospital, Jinan University, Guangzhou, China.
  • Liang H; Institute of Precision Cancer Medicine and Pathology, School of Medicine, Jinan University, Guangzhou, China.
Eur Respir J ; 59(2)2022 02.
Article in English | MEDLINE | ID: covidwho-1869041
ABSTRACT
The current pandemic of coronavirus disease 2019 (COVID-19) has affected >160 million individuals to date, and has caused millions of deaths worldwide, at least in part due to the unclarified pathophysiology of this disease. Identifying the underlying molecular mechanisms of COVID-19 is critical to overcome this pandemic. Metabolites mirror the disease progression of an individual and can provide extensive insights into their pathophysiological significance at each stage of disease. We provide a comprehensive view of metabolic characterisation of sera from COVID-19 patients at all stages using untargeted and targeted metabolomic analysis. As compared with the healthy controls, we observed different alteration patterns of circulating metabolites from the mild, severe and recovery stages, in both the discovery cohort and the validation cohort, which suggests that metabolic reprogramming of glucose metabolism and the urea cycle are potential pathological mechanisms for COVID-19 progression. Our findings suggest that targeting glucose metabolism and the urea cycle may be a viable approach to fight COVID-19 at various stages along the disease course.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: 13993003.00284-2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: 13993003.00284-2021